179 related articles for article (PubMed ID: 3919052)
1. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.
Moriondo P; Travaglini P; Nissim M; Conti A; Faglia G
J Clin Endocrinol Metab; 1985 Apr; 60(4):764-72. PubMed ID: 3919052
[TBL] [Abstract][Full Text] [Related]
2. Dihydroergocriptine in management of microprolactinomas.
Faglia G; Conti A; Muratori M; Togni E; Travaglini P; Zanotti A; Mailland F
J Clin Endocrinol Metab; 1987 Oct; 65(4):779-84. PubMed ID: 3116032
[TBL] [Abstract][Full Text] [Related]
3. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.
Molitch ME; Elton RL; Blackwell RE; Caldwell B; Chang RJ; Jaffe R; Joplin G; Robbins RJ; Tyson J; Thorner MO
J Clin Endocrinol Metab; 1985 Apr; 60(4):698-705. PubMed ID: 3882737
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
7. Does bromocriptine block thyrotropin-releasing hormone-induced prolactin release during pregnancy?
Ylikorkala O; Kivinen S; Rönnberg L; Viinikka L
J Clin Endocrinol Metab; 1980 Mar; 50(3):600-2. PubMed ID: 6766949
[TBL] [Abstract][Full Text] [Related]
8. Prolactin and thyrotropin responses to thyrotropin-releasing hormone in patients with secondary amenorrhea: the effect of bromocriptine.
Hirvonen E; Ranta T; Seppäla M
J Clin Endocrinol Metab; 1976 Jun; 42(6):1024-30. PubMed ID: 819453
[TBL] [Abstract][Full Text] [Related]
9. [Bromocriptine treatment of hyperprolactinemia].
Gauer J; Heberling HJ; Stubert B; Richardt W; Lohmann D
Z Gesamte Inn Med; 1985 Jul; 40(13):393-6. PubMed ID: 4036221
[TBL] [Abstract][Full Text] [Related]
10. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
11. Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia.
Ho KY; Smythe GA; Compton PJ; Lazarus L
Aust N Z J Med; 1985 Apr; 15(2):213-9. PubMed ID: 3927887
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinemia: comparison of thyrotropic-releasing hormone and tomography.
Shangold GA; Kletzky OA; Marrs RP; Mishell DR
Obstet Gynecol; 1984 Jun; 63(6):771-5. PubMed ID: 6427715
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.
Shimatsu A; Murabe H; Nakamura Y; Mizuta H; Ihara C; Nakao K
Endocr J; 1999 Feb; 46(1):159-65. PubMed ID: 10426581
[TBL] [Abstract][Full Text] [Related]
14. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors.
Maxson WS; Dudzinski M; Handwerger SH; Hammond CB
Fertil Steril; 1984 Feb; 41(2):218-23. PubMed ID: 6698215
[TBL] [Abstract][Full Text] [Related]
15. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas.
Lamberts SW; Verleun T; Oosterom R
Neuroendocrinology; 1982; 34(5):339-42. PubMed ID: 7078703
[TBL] [Abstract][Full Text] [Related]
16. Prolactin secretion in the empty sella syndrome, in prolactinomas and in acromegaly.
Brismar K
Acta Med Scand; 1981; 209(5):397-405. PubMed ID: 6787839
[TBL] [Abstract][Full Text] [Related]
17. The effects of transient dopamine antagonism on thyrotropin-releasing hormone-induced prolactin release in pseudopregnant rats.
Haisenleder DJ; Moy JA; Gala RR; Lawson DM
Endocrinology; 1986 Nov; 119(5):1989-95. PubMed ID: 3095097
[TBL] [Abstract][Full Text] [Related]
18. Prolactin-secreting adenomas: the preoperative response to bromocriptine treatment and surgical outcome.
Hubbard JL; Scheithauer BW; Abboud CF; Laws ER
J Neurosurg; 1987 Dec; 67(6):816-21. PubMed ID: 3681421
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of progestins on prolactin secretion.
Sitruk-Ware R; Varin C; Clair F; Maugis E; Fermanian J; Mauvais-Jarvis P
J Clin Endocrinol Metab; 1985 Mar; 60(3):575-8. PubMed ID: 3919048
[TBL] [Abstract][Full Text] [Related]
20. Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect.
Coculescu M; Simionescu N; Oprescu M; Alessandrescu D
Endocrinologie; 1983; 21(3):157-68. PubMed ID: 6635518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
